News Headlines Article

FDA panel rejects highly anticipated diet pill
USA Today

A panel of federal health experts dealt a surprising setback Thursday to an anti-obesity pill from Vivus Inc., saying the drug’s side effects outweigh its ability to help patients lose weight. The Food and Drug Administration panel voted 10-6 against Vivus’s Qnexa, citing uncertainty about the potential risks that could come with long-term use of the drug. The FDA will consider the panel’s ruling and make its own decision on the drug in coming months.